Canada Markets close in 5 hrs 47 mins
MARKETS LIVE BLOG :

STOCKS PULL BACK AFTER DOW HITS RECORD HIGH

Shares of GameStop extended gains in early trading after more than doubling during the session Wednesday

Why Citron is right about Gamestop's 'terminal decline'

Yahoo Finance’s Brian Sozzi, Julie Hyman, and Myles Udland discuss the market action for GameStop.

Latest Stories

  • Amazon shoppers are raving about this magnetic phone mount that’s 'better than any other brand'

    This $13 magnetic phone mount is a definite customer favorite with shoppers saying it's one of the few that doesn't fall while driving.

  • Global Antisense and RNAi Therapeutics Market 2021-2025: Market is Poised to Grow by $1.61 Billion - ResearchAndMarkets.com

    The "Global Antisense and RNAi Therapeutics Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.

  • Breast Cancer Diagnostics Market Research Report by Type, by Technique, by End-user - Global Forecast to 2025 - Cumulative Impact of COVID-19

    Breast Cancer Diagnostics Market Research Report by Type (Biopsy, Blood Tests, Genomic Tests, and Imaging), by Technique (Imaging, Molecular Testing, and Tissue Biopsy Tests), by End-user - Global Forecast to 2025 - Cumulative Impact of COVID-19New York, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Breast Cancer Diagnostics Market Research Report by Type, by Technique, by End-user - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p05993440/?utm_source=GNW Market Statistics:The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.1. The Global Breast Cancer Diagnostics Market is expected to grow from USD 5,286.71 Million in 2020 to USD 7,431.94 Million by the end of 2025.2. The Global Breast Cancer Diagnostics Market is expected to grow from EUR 4,635.48 Million in 2020 to EUR 6,516.46 Million by the end of 2025.3. The Global Breast Cancer Diagnostics Market is expected to grow from GBP 4,120.95 Million in 2020 to GBP 5,793.15 Million by the end of 2025.4. The Global Breast Cancer Diagnostics Market is expected to grow from JPY 564,225.92 Million in 2020 to JPY 793,176.32 Million by the end of 2025.5. The Global Breast Cancer Diagnostics Market is expected to grow from AUD 7,677.00 Million in 2020 to AUD 10,792.16 Million by the end of 2025.Market Segmentation & Coverage:This research report categorizes the Breast Cancer Diagnostics to forecast the revenues and analyze the trends in each of the following sub-markets:Based on Type, the Breast Cancer Diagnostics Market studied across Biopsy, Blood Tests, Genomic Tests, and Imaging. Based on Technique, the Breast Cancer Diagnostics Market studied across Imaging, Molecular Testing, and Tissue Biopsy Tests. The Imaging further studied across Analog Mammography, Breast Ultrasound System, Digital Mammography, Mammography, MRI Scan, and PET/CT Scan. Based on End-user, the Breast Cancer Diagnostics Market studied across Diagnostic Laboratories, Hospitals & Ambulatory Surgery Center, and Research & Academic Institutes. Based on Geography, the Breast Cancer Diagnostics Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom. Company Usability Profiles:The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Breast Cancer Diagnostics Market including Abbott Laboratories, Agilent Technologies, Inc., Ascenda BioSciences LLC, AstraZeneca, PLC, Becton, Dickinson, and Company, Bio-Rad Laboratories, Inc, Biocept, Inc., BioNTech SE, C.R. Bard, Inc., Danaher Corporation, Epigenomics Inc, F. Hoffmann-La Roche Ltd, FUJIFILM Holdings Corporation, GE Healthcare, Genomic Health, Hologic Inc., Illumina, Inc., Koninklijke Philips N.V., Leica Biosystems, Myriad Genetics, Inc., NanoString Technologies, Inc, Paragon Biosciences LLC, Questex LLC, Siemens Healthineers AG, Thermo Fisher Scientific Inc., Todos Medical, and Toshiba Corporation. Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Breast Cancer Diagnostics Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on the market offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developmentsThe report answers questions such as:1. What is the market size and forecast of the Global Breast Cancer Diagnostics Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Breast Cancer Diagnostics Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Breast Cancer Diagnostics Market?4. What is the competitive strategic window for opportunities in the Global Breast Cancer Diagnostics Market?5. What are the technology trends and regulatory frameworks in the Global Breast Cancer Diagnostics Market?6. What are the modes and strategic moves considered suitable for entering the Global Breast Cancer Diagnostics Market?Read the full report: https://www.reportlinker.com/p05993440/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

  • Jaishankar Talks to China Foreign Min, Reviews Troop Disengagement

    They also discussed the implementation of the Moscow Pact on border standoff, Jaishankar took to Twitter to inform.

  • Sturgeon has no regrets about allowing Salmond complaints to be investigated

    Nicola Sturgeon said she did not regret ‘not sweeping the complaints under the carpet’ despite the ‘difficulties’ the case has caused.

  • Over 9,000 Amazon shoppers love this multi-device charging station: 'No more cords getting tangled!'

    Declutter your space and your cords with this powerful fast-charging device that charges six devices at once while keeping them organized.

  • Global MOOCs (Massive Open Online Course) Market 2021-2025: Market is Poised to Grow by $16.01 Billion, Progressing at a CAGR of 32% - ResearchAndMarkets.com

    The "Global MOOCs Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.

  • Indus Holdings, Inc. Announces the Acquisition of Lowell Herb Co.

    THE COMBINED COMPANY WILL OPERATE UNDERTHE NEW NAME: LOWELL FARMS INC. PENDING EXCHANGE APPROVAL, THE COMPANY WILL CONTINUE TO TRADE ON THE CSE UNDER THE TICKER “LOWL” SALINAS, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Indus Holdings, Inc. ("Indus” or the “Company”) (CSE:INDS; OTCQX: INDXF), a leading, vertically-integrated, California-focused cannabis company, announced the acquisition of substantially all of the assets of the Lowell Herb Co. and Lowell Smokes trademark brands, product portfolio, and production assets from The Hacienda Group effective immediately. Lowell Herb Co. is a leading California cannabis brand that manufactures and distributes distinctive and highly regarded premium packaged flower, pre-roll, concentrates, and vape products. The Transaction is valued at approximately US$39.0 million and is comprised of a cash payment of US$4.1 million and the issuance of 22,643,678 Subordinate Voting Shares of the Company (of which 5,000,000 will be held in escrow to secure certain indemnification obligations undertaken by the sellers in the transaction).The share consideration was issued in a private placement transaction and the Company has agreed to register such shares for resale in the United States. Hacienda has agreed to continue to produce Lowell products for an interim period for the account of the Company pending completion of the transfer of certain regulatory assets. In connection with this acquisition, the Company intends to complete a change in its corporate name to Lowell Farms Inc. It is currently anticipated that the Company’s Subordinate Voting Shares and Warrants will begin trading on the Canadian Securities Exchange (CSE) effective on March 5, 2021, under the ticker symbols LOWL and LOWL.WT, and that the Subordinate Voting Shares will begin trading on the OTCQX effective on March 5, 2021, under the ticker symbol LOWLF. No action is required to be taken by existing securityholders of the Company with respect to the name change. Outstanding share and warrant certificates are not affected by the name change and do not need to be exchanged. "The combination of Indus and Lowell will create a leading producer of California cannabis and the next step for the first great American cannabis brand," said Gregory Heyman, founder of Beehouse, Lowell’s largest investor. "The Indus team’s commitment to growing excellent cannabis and the communities they serve also realizes Lowell’s mission to normalize cannabis in America." “The cannabis industry is awash in brands competing for our attention, but Lowell has risen to the top of the fray as a brand that simultaneously empowers a movement, welcomes the curious, and greets the reacquainted all with a grace and elegance that other brands can only aspire to,'' said George Allen, Chairman of the Board for Indus Holdings, Inc. “Every resource under our control will be employed in unlocking Lowell’s full potential.” The Company will provide updates to its cultivation expansion plans as well as the operational status of our greenhouse in the upcoming earnings call and release scheduled for March 2, 2021. About Indus Holdings, IncIndus Holdings, Inc. (CSE: INDS; OTCQX: INDXF) is a vertically-integrated cannabis company with advanced production capabilities, including cultivation, extraction, manufacturing, brand sales & marketing, and distribution. Founded in 2014 and based in Salinas, California, Indus offers services supporting every step of the supply chain and an extensive portfolio of award-winning brands, including Cypress Cannabis, House Weed, The Original Pot Co., MOON, Humble Flower, and Kaizen Medicinals. Indus Distribution, a division of Indus Holdings, Inc., is a leading distributor of cannabis products, servicing an extensive portfolio of brands and licensed retailers. About Lowell Herb Co.Lowell Herb Co. has elevated the perception of cannabis consumption with its sophisticated packaging and best-selling products. Based in California, Lowell Herb Co.’s ethos is reflected through its instantly recognizable bull logo that pays homage to the fight against cannabis prohibition. For more information, visit https://lowellfarms.com and follow on Instagram @lowellfarms. Investor Relations ContactBill Mitoulas416.479.9547bill@lowellfarms.com Media ContactRenata Follmannpr@lowellfarms.com Company ContactMark Ainsworth ir@lowellfarms.com Forward-Looking Information and Statements and non-IFRS Financial Measures This news release contains certain "forward-looking information" within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only Indus’ beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Indus’ control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or may contain statements that certain actions, events or results "may", "could", "would", "might" or "will be taken", "will continue", "will occur" or "will be achieved.” The forward-looking information and forward-looking statements contained herein may include, but are not limited to, the receipt of the required regulatory approvals for the transfer of the remaining target assets to the Company, the timing for the completion of the name change of the Company and the commencement of trading of the Company’s securities under the described ticker symbols, the anticipated benefits of the described acquisition, the ability of the Company to operate the acquired assets as currently contemplated and expanding its operations, the ability of the Company to successfully achieve its business objectives, including as a result of the described acquisition, and expectations for other economic, business, and/or competitive factors. There can be no assurance that such forward-looking information and statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such forward-looking information and statements. This forward-looking information and statements reflect Indus’ current beliefs and are based on information currently available to Indus and on assumptions Indus believes are reasonable. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Indus to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive applicable regulatory approvals to effect the acquisition of the remaining target assets, the name change of the Company and associated matters; operating and development costs; competition; changes in legislation or regulations affecting Indus; the timing and availability of external financing on acceptable terms; the available funds of Indus and the anticipated use of such funds; delay or inability to complete an acquisition; favorable production levels and outputs; the stability of pricing of cannabis products; the level of demand for cannabis product; the availability of third-party service providers and other inputs for Indus’ operations; lack of qualified, skilled labor or loss of key individuals; and risks and delays resulting from the COVID-19 pandemic. A description of additional assumptions used to develop such forward-looking information and a description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Indus’ disclosure documents, such as Indus’ annual information form filed on the SEDAR website at www.sedar.com. Although Indus has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Indus as of the date of this news release and, accordingly, is subject to change after such date. However, Indus expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law. Neither the Canadian Securities Exchange nor its Regulation Service Provider has reviewed, or accepts responsibility for the adequacy or accuracy of, the content of this news release.

  • England minorities: Higher COVID-19 cases, fewer vaccinated

    England’s ethnic minority communities have higher levels of COVID-19 infections and lower levels of vaccine acceptance than other groups, according to a new study that highlights how the pandemic is worsening health inequalities. The study found that 92% of people across England either have received or would accept a vaccine. Researchers also found that most people of all age groups produced disease-fighting antibodies after two doses of the Pfizer-BioNTech vaccine.

  • Editas: 4Q Earnings Snapshot

    CAMBRIDGE, Mass. (AP) _ Editas Medicine Inc. (EDIT) on Thursday reported a loss of $62.5 million in its fourth quarter. The Cambridge, Massachusetts-based company said it had a loss of $1 per share.

  • England slump to two-day Test defeat against India in Ahmedabad

    Spinner Axar Patel took five for 32 to finish with a match haul of 11 wickets.

  • Dots and Bridges Launches New YouTube Channel to the Highlight the Technology, Humanity and Culture Intersection

    Dots and Bridges LLC -- a leading consulting firm that advises businesses on how to create connections with public, private and academic stakeholders that support, secure, and transform the Nation’s 16 critical infrastructure sectors -- has launched a YouTube channel.

  • ECB Soothsaying Does Little for Bonds Caught in Global Rout

    (Bloomberg) -- The European Central Bank’s pledges to fight back against unwarranted increases in bond yields are falling on deaf ears among investors.A selloff in bonds, which pushes up yields, was stemmed only temporarily on Thursday when ECB chief economist Philip Lane said officials will use the flexibility of their emergency bond-buying program to prevent any undue tightening in financial conditions. His colleague Isabel Schnabel gave a similar message earlier in the day.Yet Germany’s 10-year bond yield climbed to the highest level since March, its French equivalent rose above zero for the first time since June, and Italian yields climbed to the highest since November. Greek 10-year yields have doubled from a record low set in December.Bond yields are on the rise globally, in part due to spillovers from the U.S. economic recovery and the nation’s planned $1.9 trillion fiscal stimulus program. That’s testing central banks elsewhere, concerned that their own recoveries aren’t yet advanced enough to cope with higher borrowing costs.What Bloomberg Economics Says...“The reason for the rise in bond yields is benign. Global GDP prospects, driven by the U.S. outlook, have improved ... Having said that, the euro area is somewhat behind the world’s largest economy in terms of its recovery, and the ECB will therefore need to closely monitor financial markets.”-David Powell. To read his report, click hereLane said that while ECB officials “always welcome the rest of the world growing more quickly,” they recognize the risk to the euro zone.He echoed ECB President Christine Lagarde’s remark this week that the ECB is “closely monitoring” bond yields, and signaled that the pace of the 1.85 trillion-euro ($2.26 trillion) pandemic bond-buying program can be stepped up if needed.“Lane didn’t tell us anything new,” said Rohan Khanna, rates strategist at UBS Group AG. “ECB bond-buying can’t prevent yields from rising if the macro outlook is one of roaring growth.”The euro area is in a particularly uncomfortable spot, with an economic contraction likely this quarter because of a slow vaccine rollout and extended virus restrictions. Its own relatively small and drawn-out fiscal stimulus means output will only return to pre-pandemic levels around the middle of 2022, a full year behind the U.S.Read more: Europe’s Recovery Choices Will Leave It a Year Behind the U.S.The ECB has pledged to keep financing conditions “favorable” through the crisis, a point that Lane reiterated. He said that term applies to “the whole transmission chain of our monetary policy -- from risk-free rates to government borrowing costs to capital markets to the terms and pricing of bank lending to firms and households.”“We don’t find any significant new messages in his remarks so far that it is enough to stop the current euro-area government bond momentum,” said Piet Christiansen, chief strategist at Danske Bank A/S.Lane also said monetary policy must do more than merely counter the shock of the coronavirus, meaning the ECB will provide support “for an extended period, even after the disinflationary pressures caused by the pandemic have been sufficiently offset.”(Updates with analysis by Bloomberg Economics after fourth paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

  • Prince William And Kate Middleton Are “Appalled” By Prince Harry And Meghan Markle’s Upcoming Tell-All

    They are also “devastated” and “aghast,” which, !!!

  • These Fancy Rubber Clogs Are The Ultimate Dog Walking Shoe

    In November, following an especially filling helping of Thanksgiving leftovers, I sat down to peruse Zara’s Black Friday sale and immediately zeroed in on a pair of clogs. They were tan, bulky-looking, and made of rubber. The pair in question, called “Lightweight Sport Sole Clogs,” brought to mind Bottega Veneta’s now-famous — or, infamous, if you ask some — bulbous, ankle-height Puddle Boots, minus the boot part and the $650 price tag. (At the time, Zara’s iteration cost $35.90, though, they all sold out after being discounted to under-$10.) They also resembled classic Crocs, albeit slightly chicer, thanks to muted colorways and a lifted sole, and featuring no holes. As someone who doesn’t do much of anything outside these days, thus eliminating any uses for an outdoor shoe, I didn’t need them at all. But I wanted them. And after spending the holidays all by my lonesome, I deserved them. Three to five business days later, they were mine. At that point, I hadn’t yet become aware of their true purpose. I wore them as “inside shoes” — footwear you slip into after ditching your germ-infested outside shoes at the door — but called them “gardening shoes,” because they resembled pairs I’d seen from outdoorsy brands like Hunter and Birkenstock. It wasn’t until I posted my clogs on social media, that I realized what their destiny really was: A cross between a Croc and a rainboot, my Zara clogs are the ultimate dog walking shoe. Soon after posting my clogs to Instagram, I got a Slack message from my coworker, entertainment editor Morgan Baila: “So you know I got a dog, right?” (Her dog Lucca has his own Instagram account named @luccabailathelagotto.) “I wanted to get Crocs because I’m running in and out all day, but then I saw your story,” she said. “Should I get Crocs or Zara?” Having become inseparable from my own Zara clogs, going as far as to purchase a second pair in black, I suggested the latter. A few weeks later, I spotted them on her feed. She wore them to walk her dog, ditching the black UGG boots she previously wore for the outings. View this post on Instagram A post shared by Morgan Baila (@morganbaila) When I asked for her review, Baila shared — quite poetically I might add — this about the style’s allure: “A mix between a Croc, a garden shoe, and a floating device, these clogs are light as air and have a comfortable sole perfect for running behind Lucca on shorts walks and playing in muddy grass,” she wrote. “They’re so ugly that they’re kinda hot.” She added that because they’re made of rubber, Lucca can also chew on them without ruining them. In her words, they’re puppy-proof. View this post on Instagram A post shared by karyn fiebich (@karynfiebich) As a proud feline-owner myself, I didn’t have any means of fact-checking her. So I called on another dog mom named Karyn Fiebich, who, like Baila, after seeing my clogs on social media, bought herself a pair. She now wears them to walk her dog, as well as make flower deliveries for her Portland-based flower shop Osa Floral. “My black lab daughter Gemma and I go on a lot of walks in varying elements,” Kiebich tells Refinery29. “Not only are rubber clogs weather-proof, but they also add a little bit of personality and drama during my every day, usually uneventful activities.” Drama is right. “It’s a ridiculously oversized, cloud-like shoe that is literally the most comfortable thing I’ve worn on my feet,” she says. Of course, Zara didn’t invent rubber clogs. As previously mentioned, the Spanish fashion brand’s take is just a slightly elevated version of Croc’s signature slip-ons, which have, too, been making the rounds in fashion. In fact, The New York Times declared that they “won 2020” in September, following Bad Bunny’s collaboration with the function-first brand. Sadly, as Zara’s been known to do, they sold out of the style soon after slashing their prices to single digits. And as winter weather approached, they were replaced with quilted snow boots and lug-soled Wellies. That being said, a quick tour of the footwear market led me to a whole slew of stylish gardening options that you (and your dog) will love just as much. If you don’t believe the cat lady, ask a fellow dog-owner — they’re probably wearing a pair right now. At Refinery29, we’re here to help you navigate this overwhelming world of stuff. All of our market picks are independently selected and curated by the editorial team. If you buy something we link to on our site, Refinery29 may earn commission. Like what you see? How about some more R29 goodness, right here?Hailey Bieber's “Ugly” Shoe Combo Is So RelatableUGGs: The “Ugly” Shoe Everyone Loves To HateBirkenstock x Valentino Is Back With A New Line

  • Wayne Pivac hails ‘highly-motivated’ George North ahead of 100th Wales cap

    North made his Test debut as an 18-year-old wing in 2010.

  • 'Get used to me': Derided Postmaster General Louis Dejoy says he's not going anywhere

    The USPS boss says his plan to make the service sustainable would include eliminating first class mail and raising prices

  • Deep Brain Stimulation Devices Market Research Report by Product, by Application, by End-user - Global Forecast to 2025 - Cumulative Impact of COVID-19

    Deep Brain Stimulation Devices Market Research Report by Product (Dual-Channel and Single Channel), by Application (Depression, Dystonia, Epilepsy, Essential Tremor, and Obsessive-Compulsive Disorder (OCD)), by End-user - Global Forecast to 2025 - Cumulative Impact of COVID-19New York, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Deep Brain Stimulation Devices Market Research Report by Product, by Application, by End-user - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p05993444/?utm_source=GNW Market Statistics:The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.1. The Global Deep Brain Stimulation Devices Market is expected to grow from USD 1,018.35 Million in 2020 to USD 1,963.38 Million by the end of 2025.2. The Global Deep Brain Stimulation Devices Market is expected to grow from EUR 892.90 Million in 2020 to EUR 1,721.52 Million by the end of 2025.3. The Global Deep Brain Stimulation Devices Market is expected to grow from GBP 793.79 Million in 2020 to GBP 1,530.44 Million by the end of 2025.4. The Global Deep Brain Stimulation Devices Market is expected to grow from JPY 108,683.74 Million in 2020 to JPY 209,542.39 Million by the end of 2025.5. The Global Deep Brain Stimulation Devices Market is expected to grow from AUD 1,478.77 Million in 2020 to AUD 2,851.08 Million by the end of 2025.Market Segmentation & Coverage:This research report categorizes the Deep Brain Stimulation Devices to forecast the revenues and analyze the trends in each of the following sub-markets:Based on Product , the Deep Brain Stimulation Devices Market studied across Dual-Channel and Single Channel. Based on Application, the Deep Brain Stimulation Devices Market studied across Depression, Dystonia, Epilepsy, Essential Tremor, Obsessive-Compulsive Disorder (OCD), Pain Management, and Parkinson’s Disease. Based on End-user, the Deep Brain Stimulation Devices Market studied across Ambulatory Surgical Centers, Hospitals, Neurology Clinics, and Research Centers. Based on Geography, the Deep Brain Stimulation Devices Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom. Company Usability Profiles:The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Deep Brain Stimulation Devices Market including 3D Systems, Inc., ANSYS, Inc, ANSYS, Inc., Autodesk Inc., Bentley Systems, Inc., Caddie Software, Cadonix Ltd., CNC Software Inc., Dassault Systèmes SE, Encore Software, FUJIFILM Holdings Corp., General Electric Co., Gstarsoft Co. Ltd, Gstarsoft Co., Ltd, Hexagon AB, IMSI Design LLC, IronCAD LLC, Kubotek USA, Menhirs NV, Nanosoft, PTC Inc, Siemens PLM Software, SmartDraw, LLC, SolidCAM GmbH, Trimble Inc., VariCAD, and ZWSOFT CO. LTD. Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Deep Brain Stimulation Devices Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on the market offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developmentsThe report answers questions such as:1. What is the market size and forecast of the Global Deep Brain Stimulation Devices Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Deep Brain Stimulation Devices Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Deep Brain Stimulation Devices Market?4. What is the competitive strategic window for opportunities in the Global Deep Brain Stimulation Devices Market?5. What are the technology trends and regulatory frameworks in the Global Deep Brain Stimulation Devices Market?6. What are the modes and strategic moves considered suitable for entering the Global Deep Brain Stimulation Devices Market?Read the full report: https://www.reportlinker.com/p05993444/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

  • Weill Neurohub Joins Forces With Genentech and Roche to Advance Neuroscience Research

    UCSF, UC Berkeley announce partnership with Genentech to speed development of therapeutics for brain diseases and CNS disorders such as Alzheimer’s.

  • UK’s Covid Alert Level Should Be Lowered, Say Chief Medical Officers

    The risk of the NHS being overwhelmed within 21 days “has receded”.